 SAN DIEGO, Feb. 17, 2021 GLOBE NEWSWIRE -- Travere Therapeutics, Inc. Nasdaq: TVTX today announced the completion of its previously announced underwritten public offering of 7,532,500 shares of its common stock at a price to the public of 26.75 per share, including 982,500 shares sold pursuant to the exercise in full of the underwriters option to purchase additional shares. All of the shares were sold by Travere. Including the option exercise, the aggregate gross proceeds from the offering were approximately 201.5 million, before deducting the underwriting discounts and commissions and offering expenses. 